Abstract
Dysregulated lncRNAs are proposed to be tightly associated with the progression of various tumors including glioblastoma (GBM). LncRNA Survival Associated Mitochondrial Melanoma-Specific Oncogenic Non-Coding RNA (SAMMSON) has been reported to be an oncogenic lncRNA in several tumors. Nevertheless, the specific role and molecular mechanism of SAMMSON in GBM progression remain unknown. Expression of SAMMSON in GBM tissues and cells was detected by qRT-PCR. CCK-8 and LDH release assays were applied to evaluate cellular viability. Invasion effect was assessed by Transwell invasion assay and western blot analysis of E-cadherin and N-cadherin expression. Apoptosis was detected using flow cytometry analysis and caspase-3 activity assay. The protein levels of phosphatidylinositol-3-kinase (PI3K), phosphorylated (p)-PI3K, protein kinase B (Akt) and p-Akt were estimated by western blot. We found that SAMMSON was highly expressed in GBM tissues and cells. SAMMSON knockdown suppressed cell viability and increased LDH release in GBM cells. Moreover, SAMMSON silencing impeded the invasive ability of GBM cells by regulating epithelial-to-mesenchymal transition (EMT). Furthermore, SAMMSON downregulation increased the apoptotic rate and caspase-3 activity in GBM cells. Additionally, it was demonstrated that the PI3K/Akt pathway was inhibited following SAMMSON silencing in GBM cells. Rescue assays revealed that activation of the PI3K/Akt pathway by 740Y-P abolished SAMMSON knockdown-induced viability reduction, invasion suppression and apoptosis in GBM cells. Taken together, lncRNA SAMMSON knockdown inhibited the malignancy of GBM cells by inactivation of the PI3K/Akt pathway.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcaro A, Guerreiro AS (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genom 8(5):271–306. https://doi.org/10.2174/138920207782446160
Bai RY, Staedtke V, Riggins GJ (2011) Molecular targeting of glioblastoma: drug discovery and therapies. Trends Mol Med 17(6):301–312. https://doi.org/10.1016/j.molmed.2011.01.011
Chakravarti A, Zhai G, Suzuki Y, Sarkesh S, Black PM, Muzikansky A, Loeffler JS (2004) The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas. J Clin Oncol 22(10):1926–1933. https://doi.org/10.1200/JCO.2004.07.193
Chen G, Cao Y, Zhang L, Ma H, Shen C, Zhao J (2017) Analysis of long non-coding RNA expression profiles identifies novel lncRNA biomarkers in the tumorigenesis and malignant progression of gliomas. Oncotarget 8(40):67744–67753. https://doi.org/10.18632/oncotarget.18832
Chen X, Kuang W, Huang H, Li B, Zhu Y, Zhou B, Yan L (2018) Knockdown of RWD domain containing 3 inhibits the malignant phenotypes of glioblastoma cells via inhibition of phosphoinositide 3-kinase/protein kinase B signaling. Exp Ther Med 16(1):384–393. https://doi.org/10.3892/etm.2018.6135
Cheng CK, Fan QW, Weiss WA (2009) PI3K signaling in glioma–animal models and therapeutic challenges. Brain Pathol 19(1):112–120. https://doi.org/10.1111/j.1750-3639.2008.00233.x
Davis ME (2016) Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs 20(5 Suppl):S2–S8. https://doi.org/10.1188/16.cjon.s1.2-8
Flynn RA, Chang HY (2014) Long noncoding RNAs in cell-fate programming and reprogramming. Cell Stem Cell 14(6):752–761. https://doi.org/10.1016/j.stem.2014.05.014
Gonzalez I, Munita R, Agirre E, Dittmer TA, Gysling K, Misteli T, Luco RF (2015) A lncRNA regulates alternative splicing via establishment of a splicing-specific chromatin signature. Nat Struct Mol Biol 22(5):370–376. https://doi.org/10.1038/nsmb.3005
Huarte M (2015) The emerging role of lncRNAs in cancer. Nat Med 21(11):1253–1261. https://doi.org/10.1038/nm.3981
Jayachandran A, Jonathan GE, Patel B, Prabhu K (2018) Primary spinal cord glioblastoma metastasizing to the cerebellum: a missed entity. Neurol India 66(3):854–857. https://doi.org/10.4103/0028-3886.232347
Jia LF, Huang YP, Zheng YF, Lyu MY, Wei SB, Meng Z, Gan YH (2014) miR-29b suppresses proliferation, migration, and invasion of tongue squamous cell carcinoma through PTEN-AKT signaling pathway by targeting Sp1. Oral Oncol 50(11):1062–1071. https://doi.org/10.1016/j.oraloncology.2014.07.010
Kou XX, Hao T, Meng Z, Zhou YH, Gan YH (2013) Acetylated Sp1 inhibits PTEN expression through binding to PTEN core promoter and recruitment of HDAC1 and promotes cancer cell migration and invasion. Carcinogenesis 34(1):58–67. https://doi.org/10.1093/carcin/bgs336
Li X, Li M, Chen J, Dai H, Wang L, Xiong Y, Zhong Y, Zhang L (2017) SAMMSON drives the self-renewal of liver tumor initiating cells through EZH2-dependent Wnt/beta-catenin activation. Oncotarget 8(61):103785–103796. https://doi.org/10.18632/oncotarget.21792
Li X, Wu C, Chen N, Gu H, Yen A, Cao L, Wang E, Wang L (2016) PI3K/Akt/mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget 7(22):33440–33450. https://doi.org/10.18632/oncotarget.7961
Li Y, Chen F, Chu J, Wu C, Li Y, Li H, Ma H (2019) miR-148-3p inhibits growth of glioblastoma targeting DNA methyltransferase-1 (DNMT1). Oncol Res 27(8):911–921. https://doi.org/10.3727/096504019x15516966905337
Luo W, Li X, Song Z, Zhu X, Zhao S (2019) Long non-coding RNA AGAP2-AS1 exerts oncogenic properties in glioblastoma by epigenetically silencing TFPI2 through EZH2 and LSD1. Aging (Albany NY) 11(11):3811–3823. https://doi.org/10.18632/aging.102018
Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129(7):1261–1274. https://doi.org/10.1016/j.cell.2007.06.009
Miao L, Jiang Z, Wang J, Yang N, Qi Q, Zhou W, Feng Z, Li W, Zhang Q, Huang B, Chen A, Zhang D, Zhao P, Li X (2019) Epithelial membrane protein 1 promotes glioblastoma progression through the PI3K/AKT/mTOR signaling pathway. Oncol Rep 42(2):605–614. https://doi.org/10.3892/or.2019.7204
Reardon DA, Mitchell DA (2017) The development of dendritic cell vaccine-based immunotherapies for glioblastoma. Semin Immunopathol 39(2):225–239. https://doi.org/10.1007/s00281-016-0616-7
Ren S, Xu Y (2019) AC016405.3, a novel long noncoding RNA, acts as a tumor suppressor through modulation of TET2 by microRNA-19a-5p sponging in glioblastoma. Cancer Sci 110(5):1621–1632. https://doi.org/10.1111/cas.14002
SAMMSON (2016) Long noncoding RNA is essential for melanoma cell viability. Cancer Discov 6(5):470. https://doi.org/10.1158/2159-8290.cd-rw2016-062
Shao L, Sun W, Wang Z, Dong W, Qin Y (2020) Long noncoding RNA SAMMSON promotes papillary thyroid carcinoma progression through p300/Sp1 axis and serves as a novel diagnostic and prognostic biomarker. IUBMB Life 72(2):237–246. https://doi.org/10.1002/iub.2158
Shingu T, Yamada K, Hara N, Moritake K, Osago H, Terashima M, Uemura T, Yamasaki T, Tsuchiya M (2003) Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells. Cancer Res 63(14):4044–4047
van Bakel H, Hughes TR (2009) Establishing legitimacy and function in the new transcriptome. Brief Funct Genom Proteom 8(6):424–436. https://doi.org/10.1093/bfgp/elp037
Vendramin R, Verheyden Y, Ishikawa H, Goedert L, Nicolas E, Saraf K, Armaos A, Delli Ponti R, Izumikawa K, Mestdagh P, Lafontaine DLJ, Tartaglia GG, Takahashi N, Marine JC, Leucci E (2018) SAMMSON fosters cancer cell fitness by concertedly enhancing mitochondrial and cytosolic translation. Nat Struct Mol Biol 25(11):1035–1046. https://doi.org/10.1038/s41594-018-0143-4
Wang H, Wang H, Zhang W, Huang HJ, Liao WS, Fuller GN (2004) Analysis of the activation status of Akt, NFκB, and Stat3 in human diffuse gliomas. Lab Investig 84(8):941–951. https://doi.org/10.1038/labinvest.3700123
Wen PY, Lee EQ, Reardon DA, Ligon KL, Alfred Yung WK (2012) Current clinical development of PI3K pathway inhibitors in glioblastoma. Neuro Oncol 14(7):819–829. https://doi.org/10.1093/neuonc/nos117
Xi J, Sun Q, Ma L, Kang J (2018) Long non-coding RNAs in glioma progression. Cancer Lett 419:203–209. https://doi.org/10.1016/j.canlet.2018.01.041
Xia SS, Zhang GJ, Liu ZL, Tian HP, He Y, Meng CY, Li LF, Wang ZW, Zhou T (2017) MicroRNA-22 suppresses the growth, migration and invasion of colorectal cancer cells through a Sp1 negative feedback loop. Oncotarget 8(22):36266–36278. https://doi.org/10.18632/oncotarget.16742
Xie H, Shi S, Chen Q, Chen Z (2019a) LncRNA TRG-AS1 promotes glioblastoma cell proliferation by competitively binding with miR-877-5p to regulate SUZ12 expression. Pathol Res Pract 215(8):152476. https://doi.org/10.1016/j.prp.2019.152476
Xie J, Wang X, Liu S, Chen C, Jiang F, Mao K, Zeng F (2019b) LncRNA SAMMSON overexpression distinguished glioblastoma patients from patients with diffuse neurosarcoidosis. NeuroReport 30(12):817–821. https://doi.org/10.1097/wnr.0000000000001278
Yang S, Cai H, Hu B, Tu J (2019) LncRNA SAMMSON negatively regulates miR-9–3p in hepatocellular carcinoma cells and has prognostic values. Biosci Rep. https://doi.org/10.1042/bsr20190615
Zhang X, Jin B, Huang C (2007) The PI3K/Akt pathway and its downstream transcriptional factors as targets for chemoprevention. Curr Cancer Drug Targets 7(4):305–316. https://doi.org/10.2174/156800907780809741
Zhao HF, Wang J, Shao W, Wu CP, Chen ZP, To ST, Li WP (2017) Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical development. Mol Cancer 16(1):100. https://doi.org/10.1186/s12943-017-0670-3
Funding
None.
Author information
Authors and Affiliations
Contributions
CL conceived and designed the study. HN and KW conducted the experiments. PX, JZ, and WL analyzed the data. HN and CL drafted the manuscript. All authors discussed the results.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Ethical Approval
All procedures performed in studies involving human participants were in accordance with the Ethics Committee of the Second People's Hospital of Huai'an.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ni, H., Wang, K., Xie, P. et al. LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway. Cell Mol Neurobiol 41, 79–90 (2021). https://doi.org/10.1007/s10571-020-00833-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10571-020-00833-2